Correction To: Management of Neurofibromatosis Type 2 Associated Vestibular Schwannomas

Affiliated to Shanghai Jiaotong University School of Medicine,Wu Hao,Service de neurochirurgie, Hôpital Pitié-Salpêtrière

DOI: https://doi.org/10.1007/s40136-021-00345-7

2021-01-01

Current Otorhinolaryngology Reports

Abstract:A Correction to this paper has been published: https://doi.org/10.1007/s40136-021-00345-7

What problem does this paper attempt to address?

Management Of Neurofibromatosis Type 2 Associated Vestibular Schwannomas (Vol 9, Pg 170, 2021)

Huan Jia,Ghizlene Lahlou,Hao Wu,Olivier Sterkers,Michel Kalamarides

DOI: https://doi.org/10.1007/s40136-021-00345-7

2021-01-01

Current Otorhinolaryngology Reports

Abstract:A Correction to this paper has been published:
Corrigendum: Atypical functional hierarchy contributed to the tinnitus symptoms in patients with vestibular schwannoma

Jiaji Lin,Na You,Xiaolong Li,Jiayu Huang,Haoxuan Lu,Jianxing Hu,Jun Zhang,Xin Lou

DOI: https://doi.org/10.3389/fnins.2023.1251234

IF: 4.3

2023-07-14

Frontiers in Neuroscience

Abstract:[This corrects the article DOI: 10.3389/fnins.2023.1084270.].

neurosciences
Correction to: Recurrent fibroblast growth factor receptor3 fusion glioblastoma treated with pemigatinib: A case report and review of the literature

DOI: https://doi.org/10.1093/noajnl/vdae116

2024-07-08

Abstract:[This corrects the article DOI: 10.1093/noajnl/vdae072.].
Corrigendum: the Visual Acuity Outcome and Relevant Factors Affecting Visual Improvement in Pediatric Sporadic Chiasmatic–Hypothalamic Glioma Patients Who Received Surgery

Chihyi Liao,Heng Zhang,Zhiming Liu,Zhe Han,Chunde Li,Jian Gong,Wei Liu,Zhenyu Ma,Yongji Tian

DOI: https://doi.org/10.3389/fneur.2022.914268

IF: 3.4

2022-01-01

Frontiers in Neurology

Abstract:[This corrects the article DOI: 10.3389/fneur.2020.00766.].
Corrigendum: An Overview of Managements in Meningiomas

Lianhua Zhao,Wei Zhao,Yanwei Hou,Cuixia Wen,Jing Wang,Pei Wu,Zaiyu Guo

DOI: https://doi.org/10.3389/fonc.2020.599431

IF: 4.7

2020-09-24

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.01523.].

oncology
Corrigendum: Prophylactic AEDs Treatment for Patients With Supratentorial Meningioma Does Not Reduce the Rate of Perioperative Seizures: A Retrospective Single-Center Cohort Study

Ming Yang,Yong-Ran Cheng,Meng-Yun Zhou,Ming-Wei Wang,Lan Ye,Zu-Cai Xu,Zhan-Hui Feng,Xun-Tai Ma

DOI: https://doi.org/10.3389/fonc.2020.638877

IF: 4.7

2021-01-18

Frontiers in Oncology

Abstract:[This corrects the article .].

oncology
Therapeutic advances in treatment of patients with neurofibromatosis type 1 and type 2

G. Popescu,Francesca Paslaru,M.C. Zaharia,M. Popescu,R.M. Gorgan

DOI: https://doi.org/10.33962/roneuro-2022-071

2023-01-05

Romanian Neurosurgery

Abstract:Background: Neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) are rare tumoral suppressor syndromes, triggered by an abnormal mutation in a tumour suppressor gene (TSG) (1). Each of these syndromes represents an orphan disease (by itself), but the tumours encountered in these patients are the most frequent lesions of the nervous system. Between the two of these diseases, NF1 presents a greater risk of malignancy, hence the importance of an accurate diagnosis and distinction between the two pathological entities. The purpose of this paper is to describe our department's practice protocol with neurofibromatosis and review the current literature regarding clinical diagnosis and management of these complex diseases. Methods: Our paper is a retrospective study that comprehends 25 patients with neurofibromatosis treated in our clinic between 2011 and 2018. Results: Our study included 16 female patients (64%) and 9 male patients (36%). The mean age at presentation was 48,7 (range 14-72 years). There were 7 cases (28%) of NF1 and 18 cases (72%) of NF2. Seven cases (28%) had a positive family history and 18 patients did not (72%). The most common symptoms at presentation were hearing loss, vertigo, and headache. Conclusions: Neurofibromatosis is a very complex disease in which the tumours may have an unforeseeable growth pattern. New tumours can grow over the years and the symptoms are unpredictable. Surgical treatment is best to be reserved for symptomatic tumours. Non-surgical procedures are also an important step of the treatment, but further studies are required to decide their effectiveness.
Correction to: Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteria

DOI: https://doi.org/10.1093/noajnl/vdae164

2024-10-04

Abstract:[This corrects the article DOI: 10.1093/noajnl/vdae128.].
Correction to: Primary gliosarcoma: epidemiology, clinical presentation, management, and survival

Ruichong Ma,Delia-Marina Alexe,Erlick A Pereira

DOI: https://doi.org/10.23736/S0390-5616.20.05218-2

Abstract:This corrects the article DOI: 10.23736/S0390-5616.17.04077-2.
Correction to: Molecular landscape of IDH-mutant primary astrocytoma Grade IV/Glioblastomas

Queenie Hoi-Wing Wong,Kay Ka-Wai Li,Wei-Wei Wang,Tathiane M. Malta,Houtan Noushmehr,Yura Grabovska,Chris Jones,Aden Ka-Yin Chan,Johnny Sheung-Him Kwan,Queenie Jun-Qi Huang,Gabriel Chun-Hei Wong,Wen-Cai Li,Xian-Zhi Liu,Hong Chen,Danny Tat-Ming Chan,Ying Mao,Zhen-Yu Zhang,Zhi-Feng Shi,Ho-Keung Ng

DOI: https://doi.org/10.1038/s41379-021-00802-0

IF: 8.209

2021-04-15

Modern Pathology

Abstract:A Correction to this paper has been published: https://doi.org/10.1038/s41379-021-00802-0

pathology
Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2

M Samii,C Matthies,M Tatagiba

DOI: https://doi.org/10.1097/00006123-199704000-00007

IF: 5.315

Neurosurgery

Abstract:Objective: Vestibular schwannomas (VSs) affect young patients with Neurofibromatosis 2 (NF-2) and cause very serious problems for hearing, facial expression, and brain stem function. Our objective was to determine a therapy concept for the right timing and indication of neurosurgical therapy. Methods: In 1000 consecutive VS resections, 120 tumors in 82 patients with NF-2 were surgically treated by the same surgeon (MS) at the Department of Neurosurgery at Nordstadt Hospital from 1978 to 1993. The mean age of the patients was 27.5 years. Sixty tumors were surgically treated in 41 male patients, and 60 tumors were surgically treated in 41 female patients. Bilateral tumor resection was performed in 38 patients (76 operations, after previous partial surgery in 15 cases elsewhere), and unilateral operations were performed in 44 patients, 5 of whom had undergone ipsi- or contralateral surgery that was performed elsewhere. The operative and clinical findings are evaluated and compared with the data of patients without NF-2. Results: In 105 cases, complete tumor resections were achieved. In 15 cases, deliberate subtotal resections were performed. These were for brain stem decompression in 4 cases and for hearing preservation in the last hearing ear in 11 cases, with successful preservation in 8 of the 11. Pre- and postoperative hearing rates were higher in male than in female patients (70% in male versus 65% in female patients before surgery and 40.5 versus 31%, respectively, after surgery). Hearing was preserved in 29 of 81 ears (36%). The rate of preservation was 24% in cases of large tumors and 57% in cases of small tumors (<30 mm). Twenty-one of 82 patients (26%) were bilaterally deaf before surgery. Twenty-five patients had uni- or bilateral hearing after surgery (i.e., 41 % of those with preoperative hearing or 30.5% of the whole group). Anatomic facial nerve preservation was achieved in 85%. The facial nerve was reconstructed intracranially at the cerebellopontine angle by sural grafting in 17 cases and by hypoglossal-facial reanimation in 5. Two deaths occurred 1 and 3 months postsurgically as a result of malignant tumor growth with brain stem dysfunction and respiratory problems. In summary, for patients with NF-2, the presentation ages are lower, tumor progression is faster, the chances of anatomic and functional nerve preservation are lower, the chances of good outcomes are best when surgery is performed early and when there is good preoperative hearing function, and the danger of sudden hearing loss is higher. The chances and danger often differ from side to side among individual patients. Conclusion: The indication and the timing of tumor resections are in some respects different from normal VS handling and are dependent on the tumor extension and related necessity of brain stem decompression and on the auditory function. As an optimal goal, completeness of resection with functional cochlear nerve preservation is formulated, and as an acceptable compromise, subtotal microsurgical resection with functional cochlear nerve preservation in the last hearing ear is suggested.
Neurofibromatosis Type 2: Hearing Preservation and Rehabilitation

H. Jia,El,M. Smail,I Mosnier,H. Wu,O. Sterkers,M. Kalamarides,D. Bernardeschi

DOI: https://doi.org/10.1016/j.neuchi.2018.09.003

IF: 1.725

2018-01-01

Neurochirurgie

Abstract:The main manifestation of neurofibromatosis type 2 (NF2) is the development of bilateral vestibular schwannomas (VS). Consequently, one of the most severe functional sequelae is bilateral sensorineural hearing loss, caused by spontaneous tumor progression and/or treatment-related damage (surgery or radiosurgery). Preserving or restoring hearing is still challenging in NF2 no matter the strategy applied to each individual based on the natural history of VS. In this review, the different strategies for hearing preservation or rehabilitation are discussed and illustrated by several cases. A decisional algorithm for NF2 patients with VS is proposed that takes into consideration the tumor size and hearing level.
Corrigendum: Precision medicine: a new era for inner ear diseases

Elisa Tavazzani,Paolo Spaiardi,Donatella Contini,Giulio Sancini,Giancarlo Russo,Sergio Masetto

DOI: https://doi.org/10.3389/fphar.2024.1385698

IF: 5.6

2024-02-28

Frontiers in Pharmacology

Abstract:This article is a correction to: Precision medicine: a new era for inner ear diseases

pharmacology & pharmacy
[Corrigendum] Clinical outcomes in primary scalp angiosarcoma

Yong Zhang,Yanwen Yan,Ming Zhu,Cheng Chen,Nanhang Lu,Fazhi Qi,Jiaqi Liu

DOI: https://doi.org/10.3892/OL.2020.12025

2020-01-01

Oncology Letters

Abstract:[This corrects the article DOI: 10.3892/ol.2019.10886.].
Correction to: Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas

Congxiao Wang,Shifeng Liu,Lijing Peng,Kaixian Zhang,Wei Li,Hao Zhang,Ying Luan,Peishun Li,Xiaokun Hu

DOI: https://doi.org/10.1186/s12885-020-07246-w

IF: 4.638

2020-08-07

BMC Cancer

Abstract:An amendment to this paper has been published and can be accessed via the original article.

oncology
Correction to: Ceramide contributes to pathogenesis and may be targeted for therapy in VCP inclusion body myopathy

DOI: https://doi.org/10.1093/hmg/ddae069

IF: 5.1214

2024-04-13

Human Molecular Genetics

Abstract:This is a correction to: Lan Weiss et al., Ceramide contributes to pathogenesis and may be targeted for therapy in VCP inclusion body myopathy, Human Molecular Genetics, Volume 29, Issue 24, 15 December 2020, Pages 3945–3953, https://doi.org/10.1093/hmg/ddaa248

genetics & heredity,biochemistry & molecular biology
Erratum: Identification of a ferroptosis-related gene signature for the prognosis of pediatric neuroblastoma

Editorial Office

DOI: https://doi.org/10.21037/tcr-2024-8

2024-11-02

Translational Cancer Research

Abstract:Editorial Office Translational Cancer Research Submitted Aug 03, 2024. Accepted for publication Sep 19, 2024. Published online Oct 24, 2024. doi: 10.21037/tcr-2024-8 Erratum to: Transl Cancer Res 2024;13:3678-94. In the July 2024 issue of Translational Cancer Research , the paper "Identification of a ferroptosis-related gene signature for the prognosis of pediatric neuroblastoma." (doi: 10.21037/tcr-24-269) by Lin et al. (1) was published with some errors in the authorship. Haiyan Chen participated in the data analysis, article writing, and revision, and provided valuable suggestions for the article. All authors acknowledged her contributions and agreed to list her as a co-corresponding author. Haiyan Chen and Junxin Wu were both corresponding authors. The correct authorship is presented as follows: Xijin Lin 1 , Kongfeng Shao 1 , Zhuangbin Lin 2 , Qiandong Liang 1 , Xiaoyan Li 1 , Haiyan Chen 3 , Junxin Wu 1,4 1 Department of Radiation Oncology, Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China; 2 Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, China; 3 Department of Radiation Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 4 Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China Contributions : (I) Conception and design: X Lin, J Wu; (II) Administrative support: Q Liang, X Li; (III) Provision of study materials or patients: Q Liang, X Li; (IV) Collection and assembly of data: X Lin, Z Lin, K Shao; (V) Data analysis and interpretation: X Lin, H Chen, J Wu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to : Junxin Wu, MD, PhD. Department of Radiation Oncology, Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou 350005, China; Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, 420 Fuma Rd, Jin'an District, Fuzhou 350014, China. Email: junxinwufj@aliyun.com; Haiyan Chen, MD, PhD. Department of Radiation Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 227 South Chongqing Road, Shanghai 200025, China. Email: chenhaiyan1220@163.com. Click here to view the updated version of the article. Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

oncology
Erratum: Peripheral Nerve Injury as Treatment for Muscle Spasticity: Understanding Mechanisms and Improving Surgical Interventions [Abstract]-Erratum

DOI: https://doi.org/10.1097/GOX.0000000000005581

2024-01-11

Abstract:[This corrects the article DOI: 10.1097/01.GOX.0000992196.49362.d9.].
Corrigendum to "Refractory Jeavons Syndrome from Birth Symptomatic to PLCB1 Mutation"

DOI: https://doi.org/10.1177/2329048X241279557

2024-08-30

Abstract:[This corrects the article DOI: 10.1177/2329048X231183524.].
Erratum: Giant cervical lymphangioma encompassing the neck great vessels (carotid artery and jugular vein): A case report: Erratum

DOI: https://doi.org/10.1097/MS9.0000000000001029

2023-06-21

Abstract:[This corrects the article DOI: 10.1097/MS9.0000000000000452.].

Correction To: Management of Neurofibromatosis Type 2 Associated Vestibular Schwannomas

Management Of Neurofibromatosis Type 2 Associated Vestibular Schwannomas (Vol 9, Pg 170, 2021)

Corrigendum: Atypical functional hierarchy contributed to the tinnitus symptoms in patients with vestibular schwannoma

Correction to: Recurrent fibroblast growth factor receptor3 fusion glioblastoma treated with pemigatinib: A case report and review of the literature

Corrigendum: the Visual Acuity Outcome and Relevant Factors Affecting Visual Improvement in Pediatric Sporadic Chiasmatic–Hypothalamic Glioma Patients Who Received Surgery

Corrigendum: An Overview of Managements in Meningiomas

Corrigendum: Prophylactic AEDs Treatment for Patients With Supratentorial Meningioma Does Not Reduce the Rate of Perioperative Seizures: A Retrospective Single-Center Cohort Study

Therapeutic advances in treatment of patients with neurofibromatosis type 1 and type 2

Correction to: Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteria

Correction to: Primary gliosarcoma: epidemiology, clinical presentation, management, and survival

Correction to: Molecular landscape of IDH-mutant primary astrocytoma Grade IV/Glioblastomas

Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2

Neurofibromatosis Type 2: Hearing Preservation and Rehabilitation

Corrigendum: Precision medicine: a new era for inner ear diseases

[Corrigendum] Clinical outcomes in primary scalp angiosarcoma

Correction to: Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas

Correction to: Ceramide contributes to pathogenesis and may be targeted for therapy in VCP inclusion body myopathy

Erratum: Identification of a ferroptosis-related gene signature for the prognosis of pediatric neuroblastoma

Erratum: Peripheral Nerve Injury as Treatment for Muscle Spasticity: Understanding Mechanisms and Improving Surgical Interventions [Abstract]-Erratum

Corrigendum to "Refractory Jeavons Syndrome from Birth Symptomatic to PLCB1 Mutation"

Erratum: Giant cervical lymphangioma encompassing the neck great vessels (carotid artery and jugular vein): A case report: Erratum